Recent reports reveal heart disease is the leading cause of death in the U.S., many of whom are younger than 45. Here's what ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Inc. reported its Q1 FY2025 earnings, revealing a net loss per share of $0.06, which was better than the projected loss of $0.08. The company's revenue reached $3.2 million, surpassing the forecast of ...